Fusion Antibodies Nominated for Irish Times InterTradeIreland Innovation Award

Share Article

Award winning UK based contract research organisation Fusion Antibodies has been nominated for an Innovation Award by The Irish Times.

Leading UK contract research organisation and antibody humanization specialist, Fusion Antibodies, has been shortlisted for a prestigious Irish Times InterTradeIreland Innovation Award. The Belfast based company was among 18 finalists announced in the Irish Times on 26 January.

Fusion Antibodies was chosen as a finalist due to the cost saving advances offered by its patented antibody humanization service and revolutionary CDRx platform. Until recently, the antibody humanization came with high costs and royalty payments, meaning that only very large pharmaceuticals had the technology required for the process. Fusion Antibodies new humanization method and pioneering new CDRx platform enables the efficient and highly scalable production of humanised antibodies, at a significantly reduced cost.

“Fusion Antibodies are honoured to be nominated for this Innovation Award. Our CDRx Antibody Humanization platform has allowed us to rapidly and successfully develop new therapeutic and diagnostic antibodies for our clients while simultaneously allowing us to grow as a company,” said Andrew Glover, Fusion Antibodies ltd.

The Irish Times InterTradeIreland Innovation Awards acknowledge and celebrate the most innovative talent across six industry categories; Agrifood, Biosciences, Creative Industries, Energy and the Environment, Manufacturing and IT and Telecommunications. Fusion Antibodies was nominated in the biosciences category, which also recognises innovation in pharmaceuticals, biotechnology and nanotechnology.

According to the Irish Times article announcing the finalists, “Fusion Antibodies has created a next-generation antibody humanization service, including a new software platform that has radically improved the speed and robustness of the design of humanised antibodies at significantly lower costs. That means smaller pharma and biotech firms along with academics can begin development work.”

The nominees will now face a panel of judges that include Dr Chris Horn, Norman Crowley of Crowley Carbon, Helen Kirkpatrick of UTV Media and Kingspan, Kevin Neary of Gamestop as well as David Woolfson of Gabriel Scientific, overall winner of the the 2012 award. The final winners will be announced at a special event which will take place at Belfast’s City Hall in April.

About Fusion Antibodies
Fusion Antibodies (http://www.fusionantibodies.com) is a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery. They are specialists in the production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With 12+ years of experience in the medical research industry, including two Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.

Fusion Antibodies provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx™ technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrew Glover
@FsnAntibodies
Follow >
Fusion Antibodies
since: 02/2011
Like >
Fusion Antibodies Ltd

Follow us on
Visit website